Was Concurrent Antibiotic Use during Immunotherapy Associated with Higher Mortality for Patients with Advanced Hepatocellular Carcinoma?

Authors:
Hu JY; Liu SY; Yuan C; Wang Y; Tong XM.

Journal:
Liver Cancer

Publication Year: 2022

DOI:
10.1159/000526944

PMCID:
PMC9982334

PMID:
36872929

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Liver Cancer

Abbreviation: Liver Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined wit…
Kudo M; Aoki T; Ueshima K and 19 more (2023) - Transparency Score: 3/6
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in…
Kudo M; Ueshima K; Saeki I and 23 more (2023) - Transparency Score: 3/6
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases.
De B; Upadhyay R; Liao K and 26 more (2023) - Transparency Score: 3/6
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Tre…
Goh MJ; Park HC; Yu JI and 8 more (2023) - Transparency Score: 3/6
Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Inter…
Cheung TT; Wai-Hung Ho D; Lyu SX and 12 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement The authors have no conflicts of interest to declare."

Evidence found in paper:

"None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025